SBT6050-101 A Phase 1/1b, Open-Label, Dose Escalation and Expansion Study of SBT6050 Alone and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Expressing HER2
Clinical Trial Grant
Awarded By
Silverback Therapeutics, Inc.
Start Date
August 17, 2021
End Date
May 26, 2022
Awarded By
Silverback Therapeutics, Inc.
Start Date
August 17, 2021
End Date
May 26, 2022